Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study
Postgraduate Medical Journal · 2025
DOI: 10.1093/postmj/qgaf062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Chengu Niu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY 14621, United States. Hauptthemen laut MEDLINE: Portal Vein, Liver Cirrhosis, Anticoagulants, Venous Thrombosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Study Purpose This study assesses the efficacy and safety of direct oral anticoagulants (DOACs) compared to traditional anticoagulants in managing portal vein thrombosis (PVT), aiming to address critical gaps in both research and clinical practice. Study Design We conducted a retrospective analysis at Rochester General Hospital from January 2011 to December 2023, involving 275 cirrhotic patients with PVT. The inclusion criteria included confirmed non-neoplastic PVT by imaging.
Results
Analysis of 275 cirrhotic patients with PVT revealed no significant differences in age and gender between those treated with anticoagulants and those untreated. The mortality rate was significantly lower in the treated group (37.7%) compared to the untreated group (51.7%; P = 0.029). Gastrointestinal bleeding was slightly more prevalent in the treated group (60.7%) than in the untreated group (58.1%; P = 0.690), though not statistically significant. A significant reduction in intracranial hemorrhage was observed in the treated group (2.5% vs. 8.5% in the untreated group; P = 0.038). In a subgroup analysis comparing the outcomes and side effects of DOACs, Warfarin, and low molecular weight heparins (LMWH) in treated PVT patients, the DOAC group showed improved survival rates compared to traditional [vitamin K antagonists (VKA)/LMWH] treatment, a log-rank test indicated significant survival improvement (chi2 (1) = 8.27, P = 0.0040). DOACs demonstrated comparable mortality rates to VKAs (34.2% vs. 34.5%, P = 0.979) and a significant survival benefit over LMWH (33.3% vs. 60.0%, P = 0.030).
Conclusion
DOAC in treating PVT among patients with liver cirrhosis, demonstrating better significant survival rate when compared to traditional anticoagulation. Key message What is already known on this topic Portal vein thrombosis (PVT) is significantly more prevalent in patients with liver cirrhosis compared to the general population, posing substantial management challenges. Previous studies have primarily focused on small cohorts and retrospective data, underscoring the need for robust, large-scale analyses to validate the efficacy and safety of direct oral anticoagulants (DOACs) versus traditional therapies. What this study adds This study provides concrete evidence from a large cohort that DOACs not only offer a survival benefit over traditional anticoagulation therapies like Warfarin and LMWH in cirrhotic patients with PVT but also maintain comparable safety profiles. These findings bridge significant gaps in current research by comparing the outcomes of modern versus traditional anticoagulant approaches in a real-world setting. How this study might affect research, practice, or policy The results advocate for the inclusion of DOACs in clinical guidelines for managing PVT in cirrhosis, potentially shifting clinical practice toward these agents. Furthermore, the detailed comparison and subgroup analyses provide a strong foundation for future randomized controlled trials, which could further refine anticoagulation strategies in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY 14621, United States.
- Department of psychiatry, Rainier Springs Behavioral Health Hospital, 2805 NE 129th St, Vancouver, WA 98686, United States.
- Division of Gastroenterology, Carillion Clinic, 3 Riverside Cir SW, Roanoke, VA 24016, United States.
- Division of Gastroenterology, Charleston Area Medical Center/CAMC Institute For Academic Medicine Program, 2930 Chesterfield Ave, Charleston, WV 25304, United States.
Zitieren
APA
Niu, C., Zhang, J., Daniel-Jose, I. D., Zachary, T., Abdullah, O., Shah, P., Basant, E., Maity, D., Abdullah, F. A., Jadhav, N., Okolo, P. I., & Ebubekir, D. (2025). Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf062
Vancouver
Niu C, Zhang J, Daniel-Jose ID, Zachary T, Abdullah O, Shah P, et al. Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf062
BibTeX
@article{Niu2025,
author = {Niu, Chengu and Zhang, Jing and Daniel-Jose, Idoate-Domench and Zachary, Teibel and Abdullah, Orakzai and Shah, Purva and Basant, Eltaher and Maity, Devam and Abdullah, Firoze A and Jadhav, Nagesh and Okolo, Patrick I and Ebubekir, Daglilar},
title = {Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study},
journal = {Postgraduate Medical Journal},
year = {2025},
doi = {10.1093/postmj/qgaf062}
}
EUVIMED